As the only national payer organization that supported robust drug pricing reform, including allowing direct government negotiation for drugs without competition, we are pleased by the White House’s announcement of the first ten drugs to be negotiated.
ACHP commends Senate Finance Committee Chairman Ron Wyden (D-OR) and Ranking Member Mike Crapo (R-ID) for their leadership to reform PBMs. ACHP supports the Committee’s bipartisan efforts to increase PBM transparency, as well as modernize the industry’s revenue models.
MA for Tomorrow: Moving Beyond the Status Quo to Advance Concrete Policy Changes for the Future of Medicare Advantage
In an op-ed for The Health Care Blog, ACHP’s President and CEO Ceci Connolly and Associate Vice President of Public Policy Michael Bagel discuss MA for Tomorrow, ACHP’s vision for the future of Medicare Advantage.
ACHP unveiled MA for Tomorrow, its vision for the future of Medicare Advantage based on five policy pillars.
ACHP is the only national payer group pushing for comprehensive drug pricing reform. Allowing Medicare to negotiate for lower prescription drug prices is an important step toward better health care for all.